Gan & Lee Pharmaceuticals. (SHA: 603087)
China flag China · Delayed Price · Currency is CNY
48.42
-1.26 (-2.54%)
Nov 13, 2024, 3:00 PM CST

Gan & Lee Pharmaceuticals. Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Nov '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Market Capitalization
28,91131,06618,42939,49974,247-
Upgrade
Market Cap Growth
14.98%68.57%-53.34%-46.80%--
Upgrade
Enterprise Value
23,84826,91813,46334,93570,382-
Upgrade
Last Close Price
48.4252.4332.4469.59130.39-
Upgrade
PE Ratio
49.1187.38-26.8756.45-
Upgrade
Forward PE
31.0411.4011.4025.8150.01-
Upgrade
PS Ratio
9.6811.9110.7610.9422.08-
Upgrade
PB Ratio
2.672.891.923.888.31-
Upgrade
P/TBV Ratio
2.662.971.984.008.53-
Upgrade
P/FCF Ratio
191.79--102.30112.63-
Upgrade
P/OCF Ratio
44.70283.8362.1236.6359.81-
Upgrade
EV/Sales Ratio
8.0910.327.869.6720.94-
Upgrade
EV/EBITDA Ratio
49.4068.22-22.2444.70-
Upgrade
EV/EBIT Ratio
95.53149.52-25.1349.75-
Upgrade
EV/FCF Ratio
158.20--90.48106.77-
Upgrade
Debt / Equity Ratio
0.000.000.000.00--
Upgrade
Debt / EBITDA Ratio
0.010.02-0.01--
Upgrade
Debt / FCF Ratio
0.02--0.04--
Upgrade
Asset Turnover
0.260.230.160.350.430.54
Upgrade
Inventory Turnover
0.840.960.680.700.640.55
Upgrade
Quick Ratio
6.626.776.0512.6513.145.66
Upgrade
Current Ratio
8.047.986.9714.1514.546.79
Upgrade
Return on Equity (ROE)
5.51%3.35%-4.45%15.21%17.08%23.97%
Upgrade
Return on Assets (ROA)
1.35%1.01%-3.94%8.54%11.38%15.50%
Upgrade
Return on Capital (ROIC)
1.48%1.11%-4.27%9.09%12.27%17.05%
Upgrade
Earnings Yield
2.04%1.09%-2.38%3.68%1.66%-
Upgrade
FCF Yield
0.52%-1.43%-3.73%0.98%0.89%-
Upgrade
Dividend Yield
0.40%0.38%-0.43%0.31%-
Upgrade
Payout Ratio
20.36%--15.46%16.30%-
Upgrade
Buyback Yield / Dilution
-3.48%-0.59%-0.46%-5.28%-5.43%-0.09%
Upgrade
Total Shareholder Return
-3.08%-0.20%-0.46%-4.85%-5.13%-0.09%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.